call Toll Free (US/Canada): +1 866 658 6826 | call+1 425 320 4776 | call (UK): +44 1865 60 0662 | call (Ind): +91 9096278110 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Benign Prostatic Hyperplasia Treatment Market
Inquire Before Buying Request for Sample

Benign Prostatic Hyperplasia Treatment Market

Home Healthcare And Pharmaceutical Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia (BPH) Treatment Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Therapy (Mono Drug Therapy, Combination Drug Therapy); By Therapeutic Class (Alpha Blockers, 5-alpha-reductase Inhibitors, Phosphodiesterase-5 Inhibitors); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

  • Published Date: July 2023
  • Report ID: BWC22256
  • Available Format: PDF
  • Page: 400

Report Overview

Rapidly aging population prone to Benign Prostatic Hyperplasia (BPH) and increasing prevalence of BPH across the world, and advancements in minimally invasive treatment options are projected to propel the expansion of the Global Benign Prostatic Hyperplasia (BPH) Treatment Market during the forecast period between 2023 and 2029.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market - Industry Trends & Forecast Report, 2029

Global benign prostatic hyperplasia (BPH) treatment market size was estimated at USD 5,977.97 million in 2022. During the forecast period between 2023 and 2029, the size of global benign prostatic hyperplasia (BPH) treatment market is projected to grow at a CAGR of 3.13% reaching a value of USD 7,381.99 million by 2029. Major growth drivers for the global benign prostatic hyperplasia (BPH) treatment market include a rising awareness among the general public regarding available treatment options. Technological advancements, such as the introduction of transurethral resection of the prostate (TURP), have also played a significant role in driving market growth. TURP is an endoscopic electrosurgical procedure that involves the removal of a portion of the prostate gland to alleviate blockage caused by abnormal growth. The expanding individual healthcare expenditure capacities and notable improvements in healthcare infrastructure, particularly in developing countries, are expected to further propel the market's expansion. The increasing prevalence of benign prostatic hyperplasia and the associated urological conditions are significant drivers of market growth. Factors such as elevated inflammatory response, sympathetic nerve activity, and oxidative stress contribute to the development of BPH, particularly in obese patients. Hormonal changes in the body are also linked to prostate enlargement and the development of BPH, thereby expanding the market for BPH medications. Also, untapped emerging economies present significant opportunities for market development due to improved healthcare infrastructure, a growing demand for unmet healthcare needs, and increased efforts in research and development (R&D). Hence, such aspects are expected to boost the expansion of global BPH market during the period in analysis.

Benign Prostatic Hyperplasia (BPH) Treatment Market

Global Benign Prostatic Hyperplasia (BPH) Treatment Market – Overview

Benign prostatic hyperplasia (BPH), commonly referred to as the enlargement of the prostate gland, tends to become more prevalent in aging men. An enlarged prostate gland can lead to urinary symptoms, such as urinary retention, and may also affect the bladder, urethra, or kidneys. Treatment options for BPH encompass a range of approaches, including prescription medications, active surveillance, monotherapy and combination therapy, phytotherapy, as well as minimally invasive and invasive surgeries. These procedures often involve the utilization of resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. Active surveillance serves as one of the primary treatment methods for BPH. This approach entails closely monitoring the condition without active intervention. Under the guidance of a urologist, regular monitoring of the BPH will take place, typically through annual physical examinations. The focus will be on identifying any new or worsening symptoms before considering further interventions. Additionally, lifestyle modifications, including dietary adjustments and exercise, are commonly recommended to prevent or manage symptoms. Active surveillance is typically suitable for men experiencing mild to moderate symptoms or those who are not significantly bothered by BPH symptoms. However, if symptoms worsen or new ones emerge, the healthcare provider may recommend transitioning to active therapy.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market

Growth Drivers

Growth in Aging World Population Prone to BPH

The market for BPH treatment is projected to be significantly influenced by the aging population, particularly individuals aged 65 and above, who are more susceptible to prostate cancer. As per the World Health Organization's 2021 data, the global population aged 60 and above is projected to nearly double from 12% to 22% between 2015 and 2050. By 2050, approximately 80% of the elderly population will reside in low and middle-income countries. The rate at which the population is aging surpasses previous trends, presenting substantial challenges for healthcare and social systems to adequately address this demographic shift. According to the World Health Organization's May 2020 report, it is estimated that by 2030, one in every six individuals worldwide will be 60 years or older. The number of individuals aged 60 and above is expected to increase from 1 billion in 2020 to 1.4 billion by 2050, while the global population of individuals aged 60 and above is projected to double and reach 2.1 billion by 2050. Moreover, between 2020 and 2050, the number of individuals aged 80 and above is expected to triple, reaching 426 million. BPH is strongly associated with advancing age, with a higher likelihood of occurrence as individuals grow older. Consequently, with the rising geriatric population, the market for BPH treatment is expected to witness robust growth during the forecast period.

Restraints

High Costs associated with BPH Treatment Procedures

The expenses related to diagnosis, medications, surgeries, and follow-up care can be substantial, limiting accessibility to treatment options for many individuals. The cost of BPH medications, such as alpha-blockers and 5-alpha reductase inhibitors, can place a financial burden on patients, particularly for those without adequate insurance coverage. The need for long-term medication use can further escalate the overall expenses for individuals managing BPH. Surgical interventions for BPH, including transurethral resection of the prostate (TURP) and other minimally invasive procedures, are also accompanied by significant costs. These procedures involve specialized equipment, hospitalization, professional fees, and post-operative care, contributing to the overall financial strain on patients. Also, follow-up visits and routine monitoring for BPH management can add to the economic burden. The need for regular check-ups, diagnostic tests, and consultations with healthcare providers can lead to additional costs that may deter some patients from seeking appropriate care. The excessive costs associated with BPH treatment procedures not only affect individuals but also impact healthcare systems and payers. Budgetary constraints and limited resources can result in barriers to accessing advanced treatment options for BPH patients.

Impact of COVID-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market

COVID-19 pandemic adversely affected the growth of global benign prostatic hyperplasia (BPH) treatment market. The healthcare system's focus on managing and containing the virus has resulted in a redirection of resources, affecting the diagnosis and treatment of non-emergency conditions such as BPH. Delayed elective surgeries, reduced outpatient visits, and disruptions in the supply chain of medications and medical devices have impacted the market. Moreover, the economic impact of the pandemic has led to financial constraints for individuals, affecting their ability to seek timely BPH treatment. However, with the gradual resumption of healthcare services and the development of vaccination programs, the market recovered in the post-pandemic period, with a renewed emphasis on addressing the unmet needs of BPH patients.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market

Segmental Coverage

Global Benign Prostatic Hyperplasia (BPH) Treatment Market – By Therapy

By therapy, the global benign prostatic hyperplasia (BPH) treatment market is bifurcated into Mono Drug Therapy and Combination Drug Therapy segments. The combination drug therapy segment held a higher market share in the global benign prostatic hyperplasia (BPH) treatment market, due to its enhanced efficacy and comprehensive approach. By combining medications with different mechanisms of action, combination therapy offers improved symptom relief and better outcomes compared to mono drug therapy. The synergistic effects of combined drugs further contribute to its popularity among healthcare providers and patients. Treatment guidelines and recommendations endorsing combination therapy, along with patient preferences for convenience, also drive its market dominance. Streamlining multiple medications into a single combination product enhances medication adherence and patient compliance. These factors collectively contribute to the prominence of combination drug therapy in the BPH treatment market.

Benign Prostatic Hyperplasia (BPH) Treatment Market Share

Global Benign Prostatic Hyperplasia (BPH) Treatment Market – By Therapeutic Class

Based on therapeutic class, the global benign prostatic hyperplasia (BPH) treatment market is divided into Alpha blockers, 5-alpha-reductase inhibitors, and Phosphodiesterase-5 inhibitors segments. The alpha blockers segment holds the highest share in the global benign prostatic hyperplasia (BPH) treatment market for several reasons. The alpha blockers have demonstrated significant efficacy in managing BPH symptoms. These medications work by relaxing the smooth muscles in the prostate and bladder, improving urine flow and alleviating urinary symptoms such as frequent urination, urgency, and incomplete emptying of the bladder. Their ability to provide rapid relief and improve overall quality of life for BPH patients has established them as a preferred treatment option. Also, alpha blockers have a long-standing history of use in BPH treatment and are supported by extensive clinical evidence. They have been extensively studied and proven effective in numerous clinical trials, earning the trust and confidence of healthcare providers. Their established safety profile and well-documented effectiveness make them a reliable choice for both physicians and patients.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market – By Region

The in-depth research report on the global benign prostatic hyperplasia (BPH) treatment market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America region holds a dominant position in the market for benign prostatic hyperplasia (BPH) treatment due to its high prevalence of BPH and associated lower urinary tract symptoms. The region's collaboration between hospitals, non-profit organizations, and companies like GlaxoSmithKline has contributed to increased awareness and resources for urological disorder treatment. Additionally, the growing geriatric population in the United States has driven market growth. The demand for early diagnosis and treatment of BPH, as a risk factor for prostate cancer, has created opportunities for market players. Ongoing research and development efforts by major industry players and initiatives to enhance prostate examination and treatment further support market growth in the United States. Thus, the United States is expected to hold a significant share in the BPH treatment market.

Competitive Landscape

Major players operating in the global benign prostatic hyperplasia (BPH) treatment market include Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Urologix, LLC, Teleflex Incorporated, Olympus Corporation, Merck & Co., Inc., Allergan plc, and Endo International plc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2022

Base Year – 2022

Estimated Year – 2023

Forecast Period – 2023–2029

Facts Covered

Revenue in USD Million

Market Coverage

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Product/ Service Segmentation

Therapy, Therapeutic Class, Region

Key Players

Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Urologix, LLC, Teleflex Incorporated, Olympus Corporation, Merck & Co., Inc., Allergan plc, Endo International plc

 

By Therapy

  • Mono drug therapy

  • Combination drug therapy

By Therapeutic Class

  • Alpha blockers

  • 5-alpha-reductase inhibitors

  • Phosphodiesterase-5 inhibitors

By Region

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East and Africa

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Increasing prevalence of BPH globally.
        2. Growing ageing population prone to BPH.
        3. Advancements in minimally invasive treatment options.
      2. Restraints
        1. High costs associated with BPH treatment procedures
        2. Adverse effects and complications associated with certain treatment options
    3. Opportunities
        1. Development of novel and more effective treatment options.
        2. Increasing investment in research and development.
      2. Challenges
        1. Intense competition among market players.
        2. Slow adoption of advanced treatment technologies in certain regions.
    4. Technology Advancements/Recent Developments
    5. Regulatory Framework
    6. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Overview
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share and Forecast
      1. By Therapy
        1. Mono drug therapy
        2. Combination drug therapy
      2. By Therapeutic Class
        1. Alpha blockers
        2. 5- alpha-reductase inhibitors
        3. Phosphodiesterase-5 inhibitors
        4. Others
      3. By Region
        1. North America
        2. Europe
        3. Asia Pacific (APAC)
        4. Latin America (LATAM)
        5. Middle East and Africa (MEA)
  5. North America Benign Prostatic Hyperplasia (BPH) Treatment Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Therapy
      2. By Therapeutic Class
      3. By Country
        1. United States
          1. By Therapy
          2. By Therapeutic Class
        2. Canada
          1. By Therapy
          2. By Therapeutic Class
  6. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Therapy
      2. By Therapeutic Class
      3. By Country
        1. Germany
          1. By Therapy
          2. By Therapeutic Class
        2. United Kingdom
          1. By Therapy
          2. By Therapeutic Class
        3. Italy
          1. By Therapy
          2. By Therapeutic Class
        4. France
          1. By Therapy
          2. By Therapeutic Class
        5. Spain
          1. By Therapy
          2. By Therapeutic Class
        6. Belgium
          1. By Therapy
          2. By Therapeutic Class
        7. Russia
          1. By Therapy
          2. By Therapeutic Class
        8. The Netherlands
          1. By Therapy
          2. By Therapeutic Class
        9. Rest of Europe
          1. By Therapy
          2. By Therapeutic Class
  7. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Therapy
      2. By Therapeutic Class
      3. By Country
        1. China
          1. By Therapy
          2. By Therapeutic Class
        2. India
          1. By Therapy
          2. By Therapeutic Class
        3. Japan
          1. By Therapy
          2. By Therapeutic Class
        4. South Korea
          1. By Therapy
          2. By Therapeutic Class
        5. Australia & New Zealand
          1. By Therapy
          2. By Therapeutic Class
        6. Indonesia
          1. By Therapy
          2. By Therapeutic Class
        7. Malaysia
          1. By Therapy
          2. By Therapeutic Class
        8. Singapore
          1. By Therapy
          2. By Therapeutic Class
        9. Vietnam
          1. By Therapy
          2. By Therapeutic Class
        10. Rest of APAC
          1. By Therapy
          2. By Therapeutic Class
  8. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Therapy
      2. By Therapeutic Class
      3. By Country
        1. Brazil
          1. By Therapy
          2. By Therapeutic Class
        2. Mexico
          1. By Therapy
          2. By Therapeutic Class
        3. Argentina
          1. By Therapy
          2. By Therapeutic Class
        4. Peru
          1. By Therapy
          2. By Therapeutic Class
        5. Rest of LATAM
          1. By Therapy
          2. By Therapeutic Class
  9. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Therapy
      2. By Therapeutic Class
      3. By Country
        1. Saudi Arabia
          1. By Therapy
          2. By Therapeutic Class
        2. UAE
          1. By Therapy
          2. By Therapeutic Class
        3. Qatar
          1. By Therapy
          2. By Therapeutic Class
        4. Kuwait
          1. By Therapy
          2. By Therapeutic Class
        5. South Africa
          1. By Therapy
          2. By Therapeutic Class
        6. Nigeria
          1. By Therapy
          2. By Therapeutic Class
        7. Algeria
          1. By Therapy
          2. By Therapeutic Class
        8. Rest of MEA
          1. By Therapy
          2. By Therapeutic Class
  10. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share Analysis, 2022
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  11. Impact of Covid-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market
  12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
    1. Astellas Pharma Inc.
    2. Eli Lilly and Company
    3. GlaxoSmithKline plc
    4. AstraZeneca plc
    5. Johnson & Johnson
    6. Pfizer Inc.
    7. Abbott Laboratories
    8. Boston Scientific Corporation
    9. Medtronic plc
    10. Urologix, LLC
    11. Teleflex Incorporated
    12. Olympus Corporation
    13. Merck & Co., Inc.
    14. Allergan plc
    15. Endo International plc
    16. Other Prominent Players
  13. Key Strategic Recommendations
  14. Research Methodology
    1.  Qualitative Research
      1.  Primary & Secondary Research
    2.  Quantitative Research
    3.  Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
    4.  Breakdown of Primary Research Respondents, By Region
    5.  Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

Figures

Figure 1       Global Benign Prostatic Hyperplasia (BPH) Treatment Market Segmentation                                                            

Figure 2       Global Benign Prostatic Hyperplasia (BPH) Treatment Market Value Chain Analysis                                                                  

Figure 3       Company Market Share Analysis, 2022                                                         

Figure 4       Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 5       Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 6       Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 7       Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Region, By Value, 2019−2029                                                         

Figure 8       North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 9       North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 10     North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 11     North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Country, By Value, 2019−2029                                                          

Figure 12     United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 13     United States Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 14     United States Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 15     Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 16     Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 17     Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 18     Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 19     Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 20     Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 21     Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Country, By Value, 2019−2029                                                              

Figure 22     Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 23     Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 24     Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 25     United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 26     United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 27     United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 28     Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 29     Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 30     Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 31     France Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 32     France Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 33     France Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 34     Spain Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 35     Spain Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 36     Spain Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 37     The Netherlands Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 38     The Netherlands Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 39     The Netherlands Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 40     Belgium Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 41     Belgium Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 42     Belgium Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 43     NORDIC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 44     NORDIC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 45     NORDIC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 46     Rest of Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 47     Rest of Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Technology, By Value, 2019−2029                                                              

Figure 48     Rest of Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 49     Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 50     Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 51     Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Deployment, By Value, 2019−2029                                                             

Figure 52     Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Country, By Value, 2019−2029                                                          

Figure 53     China Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 54     China Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 55     China Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 56     India Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 57     India Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 58     India Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 59     Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 60     Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 61     Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 62     South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 63     South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 64     South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 65     Australia & New Zealand Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                             

Figure 66     Australia & New Zealand Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                             

Figure 67     Australia & New Zealand Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                         

Figure 68     Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 69     Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 70     Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 71     Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 72     Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 73     Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 74     Singapore Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 75     Singapore Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 76     Singapore Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 77     Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 78     Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 79     Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 80     Vietnam Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 81     Vietnam Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 82     Vietnam Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 83     Rest of APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 84     Rest of APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 85     Rest of APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 86     Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 87     Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 88     Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 89     Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Country, By Value, 2019−2029                                                          

Figure 90     Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 91     Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 92     Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 93     Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 94     Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 95     Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 96     Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 97     Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 98     Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 99     Peru Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 100   Peru Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 101   Peru Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 102   Colombia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 103   Colombia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 104   Colombia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 105   Rest of LATAM Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                          

Figure 106   Rest of LATAM Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 107   Rest of LATAM Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 108   Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 109   Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 110   Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                          

Figure 111   Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Country, By Value, 2019−2029                                                               

Figure 112   Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 113   Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 114   Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 115   UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 116   UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 117   UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 118   Qatar Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 119   Qatar Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 120   Qatar Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 121   Kuwait Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 122   Kuwait Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 123   Kuwait Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 124   Iran Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 125   Iran Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 126   Iran Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 127   South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 128   South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 129   South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 130   Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 131   Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 132   Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 133   Kenya Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 134   Kenya Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 135   Kenya Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 136   Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 137   Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                         

Figure 138   Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 139   Morocco Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 140   Morocco Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 141   Morocco Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                               

Figure 142   Algeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                                 

Figure 143   Algeria Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                              

Figure 144   Algeria Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029                                                              

Figure 145   Rest of MEA Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Value (USD Billion), 2019−2029                                                         

Figure 146   Rest of MEA Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapy, By Value, 2019−2029                                                          

Figure 147   Rest of MEA Benign Prostatic Hyperplasia (BPH) Treatment Market Share, By Therapeutic Class, By Value, 2019−2029

                                                                  

List of Tables

Table 1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Region, By Value, 2019−2029

Table 4 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 5 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 6 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Country, By Value, 2019−2029

Table 7 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 8 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 9 Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 10      Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 11      Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 12      Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 13      Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Country, By Value, 2019−2029

Table 14      Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 15      Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 16      United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 17      United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 18      Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 19      Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 20      France Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 21      France Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 22      Spain Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 23      Spain Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 24      The Netherlands Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 25      The Netherlands Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 26      Belgium Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 27      Belgium Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 28      NORDIC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 29      NORDIC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 30      Rest of Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 31      Rest of Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 32      Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 33      Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 34      Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Country, By Value, 2019−2029

Table 35      China Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 36      China Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 37      India Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 38      India Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 39      Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 40      Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 41      South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 42      South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 43      Australia & New Zealand Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 44      Australia & New Zealand Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 45      Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 46      Indonesia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 47      Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 48      Malaysia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 49      Singapore Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 50      Singapore Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 51      Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 52      Philippines Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 53      Vietnam Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 54      Vietnam Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 55      Rest of APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 56      Rest of APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 57      Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 58      Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 59      Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Country, By Value, 2019−2029

Table 60      Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 61      Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 62      Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 63      Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 64      Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 65      Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 66      Peru Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 67      Peru Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 68      Colombia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 69      Colombia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 70      Rest of LATAM Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 71      Rest of LATAM Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 72      Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 73      Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Country, By Value, 2019−2029

Table 74      Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 75      Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 76      UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 77      UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 78      Qatar Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 79      Qatar Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 80      Kuwait Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 81      Kuwait Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 82      Iran Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 83      Iran Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 84      South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 85      South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 86      Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 87      Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 88      Kenya Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 89      Kenya Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 90      Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 91      Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 92      Morocco Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 93      Morocco Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 94      Algeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 95      Algeria Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 96      Rest of MEA Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapy, By Value, 2019−2029

Table 97      Rest of MEA Benign Prostatic Hyperplasia (BPH) Treatment Market Size, By Therapeutic Class, By Value, 2019−2029

Table 98      Astellas Pharma Inc. Company Overview

Table 99      Astellas Pharma Inc. Financial Overview

Table 100    Eli Lilly and Company Overview

Table 101    Eli Lilly and Company Financial Overview

Table 102    GlaxoSmithKline plc Company Overview

Table 103    GlaxoSmithKline plc Financial Overview

Table 104    AstraZeneca plc Company Overview

Table 105    AstraZeneca plc Financial Overview

Table 106    Johnson & Johnson Company Overview

Table 107    Johnson & Johnson Financial Overview

Table 108    Pfizer Inc. Company Overview

Table 109    Pfizer Inc. Financial Overview

Table 110    Abbott Laboratories Company Overview

Table 111    Abbott Laboratories Financial Overview

Table 112    Boston Scientific Corporation Company Overview

Table 113    Boston Scientific Corporation Financial Overview

Table 114    Medtronic plc Company Overview

Table 115    Medtronic plc Financial Overview

Table 116    Urologix, LLC Company Overview

Table 117    Urologix, LLC Financial Overview

Table 118    Teleflex Incorporated Company Overview

Table 119    Teleflex Incorporated Financial Overview

Table 120    Endo International plc Company Overview

Table 121    Endo International plc Financial Overview

Table 122    Other Prominent Players Company Overview

Table 123    Other Prominent Players Financial Overview

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Note: Please share the corporate email address for faster response

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: The alpha blockers segment is expected to hold the highest market share in the Global Benign Prostatic Hyperplasia (BPH) Treatment Market by therapeutic class.
Ans: Major factors driving the growth of the Global Benign Prostatic Hyperplasia (BPH) Treatment Market include increasing prevalence of BPH globally, growing ageing population prone to BPH, and advancements in minimally invasive treatment options.
Ans: Global Benign Prostatic Hyperplasia (BPH) Treatment Market size was estimated at USD 5,977.97 million in 2022.
Ans: The combination drug therapy segment is expected to hold a higher market share in the Global Benign Prostatic Hyperplasia (BPH) Treatment Market by therapy.
Ans: Key players in the Global Benign Prostatic Hyperplasia (BPH) Treatment Market include Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Urologix, LLC, Teleflex Incorporated, Olympus Corporation, Merck & Co., Inc., Allergan plc, and Endo International plc. 
array(1) {
  ["__ci_last_regenerate"]=>
  int(1732209773)
}